Literature DB >> 16150043

Extra-hepatic factor VIII expression in porcine fulminant hepatic failure.

M J Hollestelle1, P P C Poyck, J M Hollestelle, H A Marsman, J A Mourik, T M Gulik.   

Abstract

In humans, fulminant hepatic failure (FHF) is frequently associated with increased factor VIII (FVIII) levels, despite widespread liver cell death. The mechanisms leading to increased FVIII levels and cellular sites of this enhanced FVIII production are poorly understood. We studied the effect of total hepatectomy in pigs, a large-animal model of FHF, on the expression of plasma and tissue FVIII during 24-hour follow-up. Tissue FVIII expression was determined before and 24 h after hepatectomy, both at the mRNA level and immunohistochemically. The expression of plasma and tissue von Willebrand factor (VWF), the natural stabilizing carrier protein of FVIII, was also measured. Total hepatectomy elicited a gradual and sustained twofold elevation of circulating FVIII, whereas FVIII mRNA levels in various organs did not increase after hepatectomy. The half-life of FVIII increased from 7.7 to 10.3 h and VWF levels were also elevated in anhepatic pigs. The increase in the half-life of FVIII and increased levels of VWF were not sufficient to explain the rise in plasma FVIII levels. At the protein level, prominent changes in the cellular distribution of FVIII were seen in spleen and kidney. These observations suggest that in this model of FHF the lack of hepatic FVIII synthesis is adequately compensated by other organs, notably spleen and kidneys.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16150043     DOI: 10.1111/j.1538-7836.2005.01543.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  6 in total

1.  Veterinary diagnostic imaging. Lobar hepatic infarction with hemorrhage, secondary to a condition of chronic lymphocytic portal hepatitis with dissecting fibrosis and abundant copper accumulation.

Authors:  Robert Hylands
Journal:  Can Vet J       Date:  2007-02       Impact factor: 1.008

2.  Expression of human coagulation factor VIII in a human hybrid cell line, HKB11.

Authors:  Baisong Mei; Yaoqi Chen; Jianmin Chen; Clark Q Pan; John E Murphy
Journal:  Mol Biotechnol       Date:  2006-10       Impact factor: 2.695

3.  Correction of hemophilia as a proof of concept for treatment of monogenic diseases by fetal spleen transplantation.

Authors:  Anna Aronovich; Dalit Tchorsh; Helena Katchman; Smadar Eventov-Friedman; Elias Shezen; Uri Martinowitz; Bruce R Blazar; Sivan Cohen; Orna Tal; Yair Reisner
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-05       Impact factor: 11.205

Review 4.  Gene therapy for hemophilia.

Authors:  Geoffrey L Rogers; Roland W Herzog
Journal:  Front Biosci (Landmark Ed)       Date:  2015-01-01

5.  Characterization and visualization of murine coagulation factor VIII-producing cells in vivo.

Authors:  Morisada Hayakawa; Asuka Sakata; Hiroko Hayakawa; Hikari Matsumoto; Takafumi Hiramoto; Yuji Kashiwakura; Nemekhbayar Baatartsogt; Noriyoshi Fukushima; Yoichi Sakata; Katsue Suzuki-Inoue; Tsukasa Ohmori
Journal:  Sci Rep       Date:  2021-07-21       Impact factor: 4.379

6.  Deep Vein Thrombosis and Pulmonary Embolism in Liver Transplant Patients: Risks and Prevention.

Authors:  James Yip; David A Bruno; Charlotte Burmeister; Marwan Kazimi; Atsushi Yoshida; Marwan S Abouljoud; Gabriel T Schnickel
Journal:  Transplant Direct       Date:  2016-03-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.